Clinical trials: in Russia
Chronic Cholecystitis, Biliary Dyskinesia
Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia
The aim of the study is to evaluate the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in patients with chronic cholecystitis and biliary dyskinesia.
- Trial name
- NCT07595003
- Testing
- 4-MUST
- Where
- 10 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Valenta Pharm JSC
Аcute Coronary Syndrome
Registry of Acute Coronary Syndrome in the Regional Cardiovascular Center
The study is a prospective registry of patients consequently admitted to the regional cardiovascular center with a diagnosis of acute coronary syndrome, in order to study the behavior of patients from the first minutes of the…
- Trial name
- STOCS (NCT06845384)
- Where
- Russia
- Volunteers
- 555 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Sjögren Syndrome
Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome
This study was to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple doses of CFZ533 (iscalimab) in patients with Sjögren's Syndrome (SjS).
- Trial name
- TWINSS (NCT03905525)
- Testing
- CFZ533
- Where
- 71 sites in United States, Argentina and 21 more
- Volunteers
- 273 people
- Sponsor
- Novartis Pharmaceuticals
Hemorrhoidal Disease, Hemorrhoid Pain
Argon Plasma Coagulation in Open Excisional Hemorrhoidectomy
This prospective single-center randomized clinical trial evaluates whether the use of argon plasma coagulation (APC) during open excisional hemorrhoidectomy reduces postoperative pain and perioperative morbidity compared with…
- Conditions
- Hemorrhoidal Disease, Hemorrhoid Pain, Hemorrhoidectomy
- Trial name
- ARGO (NCT07587892)
- Testing
- open hemorrhoidectomy using argon plasma coagulation, open hemorrhoidectomy using momopolar coagulation
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
The primary objectives of this study are: Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with…
- Trial name
- NCT03409614
- Testing
- REGN2810, REGN2810/chemo/ipi, Chemotherapy
- Where
- 133 sites in United States, Austria and 16 more
- Volunteers
- 789 people
- Sponsor
- Regeneron Pharmaceuticals
Arterial Hypertension, Periodontitis
Clinical and Prognostic Significance of Periodontitis in Patients With Arterial Hypertension
As part of a prospective study, to evaluate the effect of periodontitis on the course of hypertension at baseline, during 6 and 12 months
- Trial name
- NCT07593768
- Testing
- Orthopantomography
- Where
- Russia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Non-small Cell Lung Cancer Metastatic
SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients
Primary Objectives: Study was designed with multiple primary endpoints analyzed on randomized participants at the time of the cut-off date for each given analysis (progression free survival [PFS] and overall survival [OS]) Study…
- Trial name
- CARMEN-LC03 (NCT04154956)
- Testing
- SAR408701, Docetaxel
- Where
- 169 sites in United States, Argentina and 24 more
- Volunteers
- 389 people
- Sponsor
- Sanofi
Melanoma, Breast Cancer
Survival Monitoring in Russian Cancer Registries
This study aims to establish a holistic framework for continuous cancer survival surveillance in Russian regions with high-quality population-based cancer registry data.
- Conditions
- Melanoma, Breast Cancer, Oncology, Colon Cancer
- Trial name
- SURVIMON (NCT06043947)
- Where
- Russia
- Volunteers
- 100,000 people
- Sponsor
- N.N. Petrov National Medical Research Center of Oncology
Myasthenia Gravis
Myasthenia Gravis Inebilizumab Trial
Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.
- Trial name
- MINT (NCT04524273)
- Testing
- inebilizumab
- Where
- 104 sites in United States, Argentina and 17 more
- Volunteers
- 238 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
The purpose of this Phase II, open-label, multicentre, single-arm study is to assess efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) in participants with locally advanced (Stage III)…
- Trial name
- LADOGA (NCT06606847)
- Testing
- Oleclumab, Durvalumab
- Where
- 11 sites in Russia
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Von Willebrand Disease
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
The main aim of the study is to check effectiveness, side effects, and tolerability of vonicog alfa (recombinant von Willebrand factor [rVWF]), with or without ADVATE, in the treatment and control of nonsurgical bleeding events…
- Trial name
- NCT02932618
- Testing
- Vonicog alfa, Antihemophilic Factor (Recombinant)
- Where
- 46 sites in United States, Austria and 11 more
- Volunteers
- 47 people
- Sponsor
- Baxalta now part of Shire
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence.
- Trial name
- NCT04622319
- Testing
- DS-8201a, T-DM1
- Where
- 482 sites in United States, Argentina and 29 more
- Volunteers
- 1,600 people
- Sponsor
- Daiichi Sankyo
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2)…
- Trial name
- NCT04380636
- Testing
- Pembrolizumab, Olaparib, Etoposide
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Thromboembolism, Anticoagulant-induced Bleeding
Optimization of Management in Patients With Cardiovascular Disease After Lower Limb Joint Replacement
The goal of the study is to evaluate the frequency of cardiovascular and thromboembolic complications in patients with cardiovascular disease after lower limb joint replacement, the influence of known risk factors and strategies…
- Trial name
- NCT06627933
- Testing
- No intervention
- Where
- Russia
- Volunteers
- 1,733 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are…
- Trial name
- ALLEGORY (NCT04963296)
- Testing
- Obinutuzumab, Acetaminophen/Paracetamol, Diphenhydramine hydrochloride
- Where
- 64 sites in United States, Argentina and 12 more
- Volunteers
- 303 people
- Sponsor
- Hoffmann-La Roche
Systemic Lupus Erythematosus (SLE)
Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of treatment with either VAY736 (ianalumab) or CFZ533 (iscalimab) in patients with systemic lupus erythematosus (SLE) to…
- Trial name
- NCT03656562
- Testing
- VAY736, CFZ533
- Where
- 31 sites in Argentina, Australia and 13 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Assess the Safety and Tolerability of Various Doses and Dosing Schedules of EnteroMix in Patients With a Histologically Confirmed Solid Tumor
Safety, Tolerability and Pharmacokinetics of EM-I-2024
The study will include adult patients of either sex with a histologically confirmed solid tumor who are ineligible for surgery and for whom all available pharmacological and radiotherapeutic options have been exhausted.
- Trial name
- EM-I-2024 (NCT07584668)
- Testing
- Two cohorts of patients: intravenous administration and intra-arterial administration with dose escalation of the drug.
- Where
- Russia
- Volunteers
- 24 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Ulcerative Colitis
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).
- Trial name
- LUCENT 2 (NCT03524092)
- Testing
- Mirikizumab SC, Mirikizumab IV
- Where
- 385 sites in United States, Argentina and 32 more
- Volunteers
- 1,328 people
- Sponsor
- Eli Lilly and Company
TME, Rectal Cancer Surgery
REsults of LOw Anterior Resections With or Without Preventive Stoma in Nonemergency Department
The purpose of this multicenter randomized non-inferiority trial is to evaluate the safety of low anterior resection for rectal cancer performed with versus without a diverting stoma in patients with a low predicted risk of…
- Conditions
- TME, Rectal Cancer Surgery, Low Rectal Cancer, Middle Rectal Cancer
- Trial name
- RELOAD (NCT07463261)
- Testing
- Without a preventive stoma, With a preventive stoma
- Where
- 7 sites in Russia
- Volunteers
- 442 people
- Sponsor
- ANO Scientific and Practical Club for the Development of Modern Medical Technologies
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.